Translational Neurodegeneration

Papers
(The TQCC of Translational Neurodegeneration is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes1196
Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential178
Excitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration169
Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond111
Advances in the development of new biomarkers for Alzheimer’s disease101
The role of pathological tau in synaptic dysfunction in Alzheimer’s diseases84
COVID-19 and Alzheimer’s disease: how one crisis worsens the other78
Gut microbiome, cognitive function and brain structure: a multi-omics integration analysis59
Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases57
Alpha-synuclein seeding shows a wide heterogeneity in multiple system atrophy56
Extensive frontal focused ultrasound mediated blood–brain barrier opening for the treatment of Alzheimer’s disease: a proof-of-concept study55
TLR2 and TLR4 in Parkinson’s disease pathogenesis: the environment takes a toll on the gut54
Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson’s disease and their targeted therapeutic approaches: a comprehensive review53
Gram-negative bacteria and their lipopolysaccharides in Alzheimer’s disease: pathologic roles and therapeutic implications52
Multitasking guardian of mitochondrial quality: Parkin function and Parkinson’s disease48
Several miRNAs derived from serum extracellular vesicles are potential biomarkers for early diagnosis and progression of Parkinson’s disease47
Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia43
Neurodegenerative diseases: a hotbed for splicing defects and the potential therapies43
Advances in retina imaging as potential biomarkers for early diagnosis of Alzheimer’s disease40
Astrocyte dysfunction in Parkinson's disease: from the perspectives of transmitted α-synuclein and genetic modulation38
Circadian disruption and sleep disorders in neurodegeneration37
Redox dysregulation as a driver for DNA damage and its relationship to neurodegenerative diseases37
The COVID-19 pandemic and Alzheimer’s disease: mutual risks and mechanisms35
Mitochondrial links between brain aging and Alzheimer’s disease34
Impaired glymphatic function in the early stages of disease in a TDP-43 mouse model of amyotrophic lateral sclerosis34
A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?33
Defective lysosomal acidification: a new prognostic marker and therapeutic target for neurodegenerative diseases33
Prodromal Parkinson's disease: hype or hope for disease-modification trials?32
Extracellular vesicles, from the pathogenesis to the therapy of neurodegenerative diseases32
The effects of transcranial direct current stimulation on gait in patients with Parkinson’s disease: a systematic review31
Parkinson’s disease–associated VPS35 mutant reduces mitochondrial membrane potential and impairs PINK1/Parkin-mediated mitophagy30
LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease29
Recent advances on the molecular mechanisms of exercise-induced improvements of cognitive dysfunction29
Mechanisms of motor symptom improvement by long-term Tai Chi training in Parkinson’s disease patients29
Targeting the overexpressed mitochondrial protein VDAC1 in a mouse model of Alzheimer’s disease protects against mitochondrial dysfunction and mitigates brain pathology29
Propagation of tau and α-synuclein in the brain: therapeutic potential of the glymphatic system28
An old weapon with a new function: PIWI-interacting RNAs in neurodegenerative diseases27
Role of dopamine in the pathophysiology of Parkinson’s disease27
Translational Neurodegeneration in the era of fast growing international brain research27
Effects of transcranial ultrasound stimulation pulsed at 40 Hz on Aβ plaques and brain rhythms in 5×FAD mice27
New perspectives on cytoskeletal dysregulation and mitochondrial mislocalization in amyotrophic lateral sclerosis26
Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial26
Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials26
Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer’s disease and cognitively unimpaired individuals26
The emerging role of furin in neurodegenerative and neuropsychiatric diseases25
Roles of physical exercise in neurodegeneration: reversal of epigenetic clock25
Melatonin ameliorates tau-related pathology via the miR-504-3p and CDK5 axis in Alzheimer’s disease25
The use of fibroblasts as a valuable strategy for studying mitochondrial impairment in neurological disorders25
Ecto-GPR37: a potential biomarker for Parkinson’s disease25
CRISPR/dCas9-Dnmt3a-mediated targeted DNA methylation of APP rescues brain pathology in a mouse model of Alzheimer’s disease24
Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer’s disease: a systematic review and meta-analysis24
Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta22
Early life adversity as a risk factor for cognitive impairment and Alzheimer’s disease22
Intestine-derived α-synuclein initiates and aggravates pathogenesis of Parkinson’s disease in Drosophila22
Language training for oral and written naming impairment in primary progressive aphasia: a review22
Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson’s disease mouse model22
Links between COVID-19 and Parkinson’s disease/Alzheimer’s disease: reciprocal impacts, medical care strategies and underlying mechanisms22
0.063595056533813